Search the Newsreel

Takeda Pharmaceutical (TAK.US) will release its earnings report on July 30.

Takeda Pharmaceutical (TAK.US) is scheduled to release its earnings report on July 30. Investors and analysts will be closely watching the report for insights into the company's financial performance. This announcement provides a specific date for the upcoming financial disclosure.

Takeda Pharmaceutical Co., Ltd. Revenue Breakdown – OTC:TKPHF

Takeda Pharmaceutical Co., Ltd. (OTC:TKPHF) generated 28.38 billion USD in revenue last year. Its top-performing segment was Digestive System Diseases, contributing 8.86 billion USD, and the United States was the largest regional contributor with 13.63 billion USD. This data provides a breakdown of the …

Take-Two Interactive Software, Inc. Revenue Breakdown – NASDAQ:TTWO

Takeda Pharmaceutical Co Ltd (TAK) Valuation: PE, PB & Fair Value Analysis

Take-Two Interactive Software, Inc. $TTWO Shares Acquired by Inceptionr LLC

Inceptionr LLC significantly increased its stake in Take-Two Interactive Software (NASDAQ:TTWO) by 650.6% in the first quarter, now owning 8,820 shares worth $1.74 million. Other institutional investors like Norges Bank, AQR Capital Management LLC, and Alyeska Investment Group also made substantial acquisitions, indicating strong …

China Merchants Starts Takeda Pharmaceutical at Buy with 6,600 Yen Price Target

China Merchants has initiated coverage on Takeda Pharmaceutical with a "Buy" rating and set a price target of 6,600 Yen. This recommendation indicates a positive outlook from the firm regarding Takeda's stock performance. The article also mentions recent news about Takeda's dengue vaccine approval …

Take-Two Interactive Software, Inc. (TTWO) Stock Price, News, Quote & History

This Yahoo Finance page provides a comprehensive overview of Take-Two Interactive Software, Inc. (TTWO) stock, including its current price, historical data, news, financial performance, and analyst ratings. A significant focus is on the upcoming release of Grand Theft Auto VI, with several news articles …

TAK|Takeda Pharmaceutical Co Ltd|Price:16.835|Chg%:-0.035

Takeda Pharmaceutical Co Ltd (TAK) shows stable fundamentals, high growth potential, and is considered fairly valued within the Pharmaceuticals industry. Institutional ownership is high, and analysts recommend "Buy" with a target price of $21.13. The stock is currently trading sideways, suggesting suitability for range-bound …

Take-Two Interactive Software, Inc. (NASDAQ:TTWO) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Take-Two Interactive Software, Inc. (NASDAQ:TTWO) has received a "Moderate Buy" consensus rating from analysts, with an average 1-year price target of $294.44. Recent analyst reports have been largely positive, increasing price targets and reaffirming "Buy" or "Overweight" ratings. However, insiders including President Karl Slatoff …

Assetmark Inc. Increases Holdings in Takeda Pharmaceutical Co. $TAK

Assetmark Inc. significantly increased its stake in Takeda Pharmaceutical Co. by 45.8% in the first quarter of 2026, holding 227,616 shares valued at $4.2 million. Other institutional investors like Royal Bank of Canada and Goldman Sachs also boosted their holdings, contributing to hedge funds …

Takeda Pharmaceutical (TAK) to Announce Quarterly Earnings on Thursday

Takeda Pharmaceutical (NYSE:TAK) is scheduled to announce its Q1 2027 earnings before market open on Thursday, July 30th. Analysts are forecasting earnings of $0.1689 per share and revenue of $7.1469 billion for the quarter. The company's stock currently has an average "Hold" rating from …

Takeda wins China approval for narcolepsy drug ORZEYFUL

Takeda's China unit has received approval from China's National Medical Products Administration for ORZEYFUL (oveporexton) to treat narcolepsy type 1 in patients aged 16 and older. This drug is the first approved selective orexin 2 receptor agonist in China, targeting the underlying orexin deficiency …

Takeda gets first OK for orexin narcolepsy drug, in China

Takeda has received the first global approval for its orexin agonist, oveporexton (Orzeyful), in China for treating narcolepsy type 1 in adults and adolescents aged 16 and over. This approval represents a significant shift from symptomatic treatment to a mechanism-driven approach for narcolepsy, addressing …

Take-Two Interactive Software, Inc. $TTWO Shares Acquired by Davis R M Inc.

Davis R M Inc. increased its stake in Take-Two Interactive Software, Inc. (NASDAQ:TTWO) by 4.3% in the first quarter, now owning 255,075 shares valued at over $50 million. Other institutional investors also adjusted their positions in the company. Analysts hold a "Moderate Buy" consensus …

Andra AP fonden Takes $6.32 Million Position in Take-Two Interactive Software, Inc. $TTWO

Andra AP fonden has acquired a new position in Take-Two Interactive Software, Inc. (NASDAQ:TTWO) during the first quarter, purchasing 32,000 shares valued at approximately $6.32 million. Other institutional investors also adjusted their holdings in the company, which saw its stock trading down 1.0% at …

SEB Asset Management AB Invests $8.65 Million in Take-Two Interactive Software, Inc. $TTWO

SEB Asset Management AB has invested $8.65 million in Take-Two Interactive Software, Inc. (NASDAQ:TTWO) by purchasing 43,786 shares in the first quarter. This article also details other institutional investor activity, significant insider stock sales by company executives, and recent analyst ratings which generally recommend …

India approves its first dengue vaccine, from Japan's Takeda

India has approved Takeda Pharmaceutical's dengue vaccine, making it the country's first such vaccine. This move aims to tackle the dramatic increase in dengue cases in India, which have soared elevenfold over the past two decades. The approval by Indian regulators is a significant …

(TTWO) Movement as an Input in Quant Signal Sets

This article provides an AI-generated analysis of Take-two Interactive Software Inc. (NASDAQ: TTWO), highlighting weak near and mid-term sentiment but a neutral long-term outlook. It details three trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The report also …

Take-Two Interactive Software, Inc. $TTWO Shares Sold by Jennison Associates LLC

Jennison Associates LLC reduced its stake in Take-Two Interactive Software (NASDAQ:TTWO) by 8.2% in the first quarter, selling 20,788 shares and retaining 231,409 shares valued at $45.7 million. Despite institutional selling, analysts generally maintain a "Moderate Buy" rating with an average price target of …

DJE Kapital AG Makes New $9.99 Million Investment in Take-Two Interactive Software, Inc. $TTWO

DJE Kapital AG initiated a new position in Take-Two Interactive Software (NASDAQ:TTWO) during the first quarter, acquiring shares worth approximately $9.99 million. This investment highlights continued institutional interest in TTWO, with several large funds increasing their stakes. Analyst sentiment for the stock is generally …

California Public Employees Retirement System Sells 76,189 Shares of Take-Two Interactive Software, Inc. $TTWO

The California Public Employees Retirement System (CalPERS) reduced its stake in Take-Two Interactive Software, Inc. (NASDAQ:TTWO) by 24.2% in the first quarter, selling 76,189 shares and holding 238,705 shares valued at $47.14 million. This move is part of broader institutional trading activity, with other …

Roblox vs. Take-Two: Which Gaming Stock Has the Edge Now?

This article analyzes Roblox (RBLX) and Take-Two Interactive Software (TTWO) to determine which gaming stock presents a stronger investment case. Roblox is highlighted for its expanding user engagement, creator economics, and AI capabilities, despite a lowered full-year bookings outlook. Take-Two faces an uneven fiscal …

Novartis and Takeda drugs gain rare blood cancer routine use on NHS

Novartis' Tafinlar and Takeda's Adcetris in combination with bendamustine have gained routine use on the NHS for rare blood cancers, benefiting approximately 200 patients annually. These drugs offer additional therapeutic options, particularly for cases where other treatments have failed, and align with the UK’s …

Takeda Pharmaceutical Company L (TAK) Stock Analysis: A 22.51% Potential Upside with a Strong Buy Consensus

Takeda Pharmaceutical Company L (NYSE: TAK) presents a strong investment opportunity in the healthcare sector, backed by a robust market capitalization, diverse product portfolio, and attractive 3.60% dividend yield. Despite some negative financial metrics like EPS and ROE, its $672.78 billion free cash flow …

Take-Two Stock Guided to 20% Growth. GTA VI’s Date Is Why.

Take-Two Interactive is projected for significant growth in fiscal year 2027, with net bookings guided to $8 billion to $8.2 billion, a 20% increase, primarily driven by the confirmed November 19 release of Grand Theft Auto VI. Despite this optimistic outlook and strong analyst …

Japanese drugmaker Takeda's QDENGA becomes first dengue vaccine approved in India

Takeda Pharmaceutical's dengue vaccine QDENGA has been approved by India's drug regulator, making it the first such vaccine cleared in the country. This two-dose vaccine is effective against all four dengue virus serotypes and is indicated for ages 4 to 60, with high efficacy …

Take-Two Interactive Software, Inc. $TTWO Shares Bought by Mediolanum International Funds Ltd

Mediolanum International Funds Ltd increased its stake in Take-Two Interactive Software, Inc. (NASDAQ:TTWO) by 41.0% in the first quarter, now owning 279,609 shares valued at $53,987,000. Other hedge funds also adjusted their holdings, and institutional investors collectively own 95.46% of the stock. Meanwhile, company …

Take-Two Interactive Software, Inc. $TTWO Shares Sold by Bank of New York Mellon Corp

Bank of New York Mellon Corp decreased its stake in Take-Two Interactive Software by 6.6% in the first quarter, selling 66,779 shares. Despite this, institutional ownership remains high at 95.46%, with several other institutional investors increasing their holdings. Wall Street analysts have a "Moderate …

How Investors Are Reacting To Take-Two Interactive Software (TTWO) Spotlighting Grand Theft Auto VI Over Earnings

Jefferies analysts highlight that investor sentiment for Take-Two Interactive Software (TTWO) is now primarily driven by the timing and scope of Grand Theft Auto VI (GTA VI), particularly its online component, rather than near-term quarterly performance. This focus on GTA VI's launch plans could …

Takeda Pharmaceutical Company (4502) Q4 2025 earnings summary

Takeda Pharmaceutical Company reported strong FY2024 results with core revenue growth of 2.8% and a 4.9% increase in core operating profit at constant exchange rates, driven by growth and launch products. The company also announced an increased dividend of JPY 200 per share and …

Takeda Pharmaceutical (TSE:4502) After Psoriasis Data And FDA Filing Plans Still Looks Undervalued

Takeda Pharmaceutical's recent Phase 3 data for its psoriasis drug zasocitinib and plans for FDA filing have put the stock back in the spotlight. Despite a strong performance with over 31% shareholder return in the past year, the company's shares are still considered undervalued …

GTA VI Release Date Confirmed? Take-Two SEC Filing Forecasts $1 Billion Cash Flow

Photo by BeInCrypto Take-Two Interactive confirmed GTA VI's release date in a formal SEC filing.The preliminary proxy statement set November 19, 2026, and framed fiscal 2027 as a turning point. CEO Strauss Zelnick called the coming year a major inflection point. He cited record …

Take-Two Interactive Software (TTWO) Proxy filing Summary

Take-Two Interactive Software (TTWO) has filed its proxy statement, summarizing a strong Fiscal 2026 with $6.72B in Net Bookings, driven by titles like NBA 2K and Grand Theft Auto. Fiscal 2027 is projected to be a major inflection point with the release of Grand …

Take-Two Interactive set for in-line quarter as investor focus remains on GTA VI

Take-Two Interactive is expected to report an in-line first fiscal quarter, with investor attention primarily focused on updates regarding Grand Theft Auto VI (GTA VI). Jefferies analysts anticipate muted expectations for the quarter, largely due to weakness in the company's mobile business, but maintain …

Oral Psoriasis Drug From Takeda Demonstrates Strong Skin Clearance in Trials

Takeda Pharmaceutical's oral psoriasis drug, zasocitinib, showed strong skin clearance in Phase 3 trials, with approximately 70% of patients achieving clear or nearly clear skin within 16 weeks, including in difficult-to-treat areas like the scalp and nails. The drug demonstrated rapid and sustained improvements …

Takeda reports zasocitinib psoriasis trial results at AAD meeting

Takeda Pharmaceutical Company announced positive secondary endpoint data from two Phase 3 studies of zasocitinib, an investigational oral therapy for moderate-to-severe plaque psoriasis, at the American Academy of Dermatology Innovation Academy. The results showed significant improvements in scalp and palmoplantar psoriasis compared to placebo. …